Innovation

Metabolically Stable, Non-Nephrotoxic Puromycin Analogs as Oncology and Anti-infective Therapeutics

Medical University of South Carolina
posted on 03/28/2011

The synthesized compounds are novel analogs of Puromycin that have maintained the same antimicrobial and antitumor activities of the naturally occurring form, but block the formation of toxic by-products. These new analogs may provide promising chemotherapeutic agents that have the same effectiveness of Puromycin without the nephrotoxicity. In preliminary studies, the target compound showed cytotoxicity in breast cancer and leukemia cell lines at levels comparable to Puromycin.

 

 

Overview:

Puromycin is a long-known antibiotic agent derived from the bacteria Streptomyces alboniger. By mimicking the 3'-end of aminoacyl-tRNA, Puromycin inhibits amino acid synthesis during translation. While Puromycin has clear scope for use as an antitumor agent, its metabolic conversion to Puromycin aminonucleoside (PAN) has potent, nephrotoxic side effects that have limited its potential for clinical use. To fully exploit Puromycin as an anticancer agent, it is necessary to develop a metabolically stable analog that retains the same antimicrobial and antitumor properties as the original compound, but lacks the nephrotoxicity.

 

Advantages:

Decreased nephrotoxicity with comparable cytotoxicity

 

Key Words: Cancer, antitumor agent, antibacterial, Puromycin

 

Publications: Gilbert, Carrie LK, et al. "Synthesis of l, l-puromycin." Tetrahedron 61.35 (2005): 8339-8344.

 

Inventors:                                  G. Gumina, R. White

Patent Status:                         US Patent 7,897,759

MUSC-FRD Technology ID:    P0709

 


Innovation Details
 

File Number: P0709 


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact Marketing / Licensing Officer at Medical University of South Carolina for more information.

Request more info via email request more info
People

Principal Investigator:

Giuseppe Gumina Giuseppe Gumina

Innovations (2)



Co-Investigators:

Roger White Roger White

Innovations (1)

Case Manager:

Marketing / Licensing Officer Marketing / Licensing Officer

Innovations (60)


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Communities
Profile
Related Tags

Find more innovations


February 11, 2009

13,277 members 17,569 innovations 176 organizations

Browse

David Kolb, CEO and chairman of the board, Emunamedica LLC.

"We found tremendous value and benefit in using the iBridge Network..."  read more...